Association of statin use with peripheral neuropathy in the US population 40 years of age or older

Journal of Diabetes

Volumn 5, Issue 2, 2013, Pages 207-215

  Tierney, Edward F ^a   Thurman, David J ^a   Beckles, Gloria L ^a   Cadwell, Betsy L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Diabetes; Peripheral neuropathy; Statin use

Indexed keywords

CYANOCOBALAMIN; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEAD;

ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BODY HEIGHT; BODY WEIGHT; DIABETES MELLITUS; DRUG USE; ETHNICITY; FEMALE; GENDER; HEALTH STATUS; HEALTH SURVEY; HUMAN; HYPERTENSION; LEAD BLOOD LEVEL; MALE; PERIPHERAL NEUROPATHY; POVERTY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DIABETIC NEUROPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; RISK FACTORS;

EID: 84877085391     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12013     Document Type: Article

References (63)

1. Ropper AH, Brown RH. Diseases of the Peripheral Nerves. In: Ropper AH, Brown RH, (eds). Adams and Victor's Principles of Neurology. McGraw-Hill, New York, 2005; 1110-77.
2. Gregg EW, Sorlie P, Paulose-Ram R et al. Prevalence of lower-extremity disease in the U.S. adult population ≥40 years of age with and without diabetes:1999-2000 National Health and Nutrition Examination Survey. Diabetes Care. 2004; 27: 1591-7.
3. Gregg EW, Gu Q, Williams D et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 and older. Diabetes Res Clin Pract. 2007; 77: 485-8.
4. Jukema JW, Bergheanu SC. Statins: Established indications and controversial subgroups. Heart. 2008; 94: 1656-62.
5. Bjorck L, Welin C, Rosengren A. Secular trends in lipid-lowering treatment and lipid levels after a first acute myocardial infarction. Vasc Health Risk Manag. 2007; 3: 1045-51.
6. Chiang C-W, Chiu H-F, Chen C-Y, Wu H-L, Yang C-Y. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf. 2008; 17: 62-9.
7. DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischemic heart disease in the UK 1994 2005: Use of individual and combination treatment. Heart. 2008; 94: 83-8.
8. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: A case of agism but not sexism. Heart. 2003; 89: 417-21.
9. Eurich DT, Gamble J-M, Simpson SH, Johnson JA. The darkening cloud of diabetes. Diabetes Care. 2008; 31: 2136-42.
10. Goldberg RJ, Spencer FA, Steg PG et al. Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: A multinational perspective. Arch Intern Med. 2007; 167: 1766-73.
11. Levy AR, O'Brien BJ, McMullen E et al. Rapid increase in statins newly dispensed to Ontario seniors between 1994 and 2000. Can J Cardiol. 2003; 19: 665-9.
12. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005; 2: 434-40.
13. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: Impact of the 2001 National Cholesterol Education Program Guidelines. Ann Pharmacother. 2008; 42: 1208-15.
14. Mantel-Teeuwisse AK, Klungel OH, Verschuren WMM, Porsius AJ, deBoer A. Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol. 2002; 53: 379-85.
15. Neutel CI, Morrison H, Campbell NRC, deGroh M. Statin use in Canadians: Trends, determinants and persistence. Can J Public Health. 2007; 98: 412-6.
16. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons ≥65 years of age. Am J Cardiol. 2007; 100: 1061-7.
17. Teeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: Analysis of prescribing trends 1998-2002. Br J Clin Pharmacol. 2005; 59: 227-32.
18. Walley T, Folino-Gallo P, Stephens P, Van Ganse E, on behalf of the EuroMedStat Group. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol. 2005; 60: 543-51.
19. Baker SK, Tamopolsky MA. Statin-associated neuromyotoxicity. Drugs Today. 2005; 41: 267-93.
20. Christopher-Stine L. Statin myopathy: An update. Curr Opin Rheumatol. 2006; 18: 647-53.
21. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep. 2005; 57: 23-34.
22. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: Incidence, risk factors, and pathphysiology. Curr Artheroscler Rep. 2007; 9: 389-96.
23. Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc. 2006; 46: 479-89.
24. Bottorff MB. Statin safety and drug interaction: clinical implications. Am J Cardiol. 2006; 97(Suppl. 1): S27-31.
25. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology. 2004; 62: 670.
26. Ahn SC. Neuromuscular complications of statins. Phys Med Rehabil Clin N Am. 2008; 19: 47-59.
27. Bayes H. Statin safety: An overview and assessment of the data: 2005. Am J Cardiol. 2006; 97(Suppl. 1): S6-26.
28. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: An appraisal from the adverse event reporting system. Am J Cardiol. 2006; 97(Suppl. 1): S32-43.
29. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: An analysis of individual case safety reports from Vigibase. Drug Saf. 2007; 30: 515-25.
30. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol. 2006; 97(Suppl. 1): S52-60.
31. de Langen JJ, van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy: Reports to the Netherlands Pharmacovigilance Centre. Neth J Med. 2006; 64: 334-8.
32. Ahmad S. Lovastatin and peripheral neuropathy. Am Heart J. 1995; 130: 1321.
33. Jacobs MB. HMG-CoA reductase inhibitor therapy and peripheral neuropathy. Ann Intern Med. 1994; 120: 970.
34. Jeppesen U, Gaist D, Smith T, Sindrup SH. Statins and peripheral neuropathy. Eur J Clin Pharmacol. 1999; 54: 835-8.
35. Lo YL, Leoh TH, Loh LM, Tan CE. Statin therapy and small fibre neuropathy: A serial electrophysiological study. J Neurol Sci. 2003; 208: 105-8.
36. Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern J-P. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry. 1995; 58: 625-8.
37. Ziajka PE, Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. South Med J. 1998; 91: 667-8.
38. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother. 2003; 37: 274-8.
39. Chong PH, Boskovich A, Stevkovic N, Bartt RE. Statin-associated peripheral neuropathy: Review of the literature. Pharmacotherapy. 2004; 24: 1194-203.
40. Peltier AC, Russell JW. Advances in understanding drug-induced neuropathies. Drug Saf. 2006; 29: 23-30.
41. Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol. 2005; 18: 574-80.
42. Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2003; 3: 86-92.
43. Corrao G, Zambon A, Bertu L, Botteri E, Leoni O. Lipid lowering drugs prescription and the risk of peripheral neuropathy: An exploratory case-control study using automated databases. J Epidemiol Community Health. 2004; 58: 1047-51.
44. Gaist D, Jeppesen U, Anderson M, Garcia Rodriquez LA, Hallas J, Sindrup SH. Statins and the risk of polyneuropathy: A case-control study. Neurology. 2002; 58: 1333-7.
45. Gaist D, Garcia Rodriquez LA, Huerta C, Hallas J, Sindrup SH. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol. 2001; 56: 931-3.
46. National Center for Health Statistics. National Health and Nutrition Examination Survey. Available from: http://www.cdc.gov/nchs/about/major/nhanes/intro_mec.htm (accessed 25 January 2012).
47. National Center for Health Statistics. National Health and Nutrition Examination Survey 1999-2000 Data Release. Lower Extremity disease examination (LEX), MEC examination. Available from: http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/LEXPN.htm (accessed 14 November 2012).
48. Cheng YJ, Gregg EW, Kahn HS, Williams DE, DeRekeneire N, Narayan KM. Peripheral insensate neuropathy: A tall problem for US adults. Am J Epidemiol. 2006; 164: 873-80.
49. Raghunathan TE, Solenberger P, Van Hoewyk J. IVEware: Imputation and Variance Estimation Software User Guide. Ann Arbor:Survey Methodology Program, Survey Research Center, Institute for Social Research, University of Michigan. Available from: ftp://ftp.isr.umich.edu/pub/src/smp/ive/ive_user.pdf (accessed 25 January 2012).
50. Davis TME, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: The Fremantle Diabetes Study. Diabetologia. 2008; 51: 562-6.
51. Fried LF, Forest KYZ, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: Effect on microvascular outcomes. J Diabetes Complications. 2001; 15: 113-9.
52. Gulcan E, Gulcan A, Erbilen E, Toker S. Statins may be useful in diabetic foot ulceration treatment and prevention. Med Hypotheses. 2007; 69: 1313-5.
53. Leiter LA. The prevention of diabetic microvascular complications of diabetes: Is there a role for lipid lowering? Diabetes Res Clin Pract. 2005; 68(Suppl. 2): S3-14.
54. Bifulco M, Malfitano AM, Marasco G. Potential therapeutic role of statins in neurological disorders. Expert Rev Neurother. 2008; 8: 827-37.
55. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: Diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract. 2003; 61(Suppl. 1): S35-9.
56. Ii M, Nishimuro H, Kusano KF et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation. 2005; 112: 93-102.
57. Focking M, Besselmann M, Trapp T. Statins potentiate caspase-3 activity in immortalized murine neurons. Neurosci Lett. 2004; 355: 41-4.
58. Chazerain P, Hayem G, Hamza S, Best C, Ziza J-M. Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine. 2001; 68: 430-3.
59. Otruba P. Treatments with statins and peripheral neuropathy: Results of 36-months a prospective clinical and neurophysiological follow-up. Neuro Endocrinol Lett. 2011; 32: 688-90.
60. Joy TR, Hegele RA. Narrative review: Statin-related myopathy. Ann Intern Med. 2009; 150: 858-68.
61. Deambrosis P, Saramin C, Terrazzani G et al. Evaluation of the prescription and utilization patterns of statins in an Italian local Elath unit during the period 1994-2003. Eur J Clin Pharmacol. 2007; 63: 197-203.
62. Donnelly LA, Doney ASF, Morris AD, Palmer CAN, Donnan PT. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008; 25: 850-5.
63. Wald DS, Morton G, Walker K, Iosson N, Curzen NP. Long-term continuation drug treatment in patients with coronary heart disease. Ann Pharmacother. 2007; 41: 1644-7.